Ignite Creation Date:
2025-12-24 @ 2:32 PM
Ignite Modification Date:
2026-06-14 @ 4:10 AM
Study NCT ID:
NCT05896059
Status:
RECRUITING
Last Update Posted:
2023-06-09
First Post:
2023-05-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Sponsor:
Zhejiang Cancer Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Extensive Stage Small Cell Lung Cancer | View |
Keywords: